Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Kazia Therapeutics: GDC-0084 Phase Ii To Begin Shortly

Published 12/21/2017, 05:15 AM
Updated 07/09/2023, 06:31 AM

Novogen has changed its name to Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) and undertaken a 10:1 share consolidation following shareholder approval in November. It has also out-licensed its preclinical super-benzopyran development programme, and has added a dose optimisation lead-in component to the Phase II trial of GDC-0084 in glioblastoma, which is expected to commence in early 2018. Although the more focused pipeline and longer Phase II trial for GDC-0084 prompts us to trim our valuation to between A$69m and A$127m, we believe the changes will be positive in the long run, increasing the chance of success in the GDC-0084 development programme.

Kazia Therapeutics

GDC-0084 Phase II to start early in the new year

Kazia is on track to initiate a Phase II study of its oral PI3K inhibitor GDC-0084 in glioblastoma early in the new year. It has received its first ethics committee approval and the US site will open for recruitment in early 2018. The trial design now includes a lead-in component to optimise dosing before the randomised study begins. Identifying an optimised dosing regimen would be likely to increase the prospects of success for the Phase II study, which compensates for the extra 12-15 months it is expected to add to the overall Phase II programme. The open-label lead-in should provide an initial data readout in late 2018 or early 2019.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.